# ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

> **NCT01730612** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 23 (actual)

## Conditions studied

- HER2 Negative Breast Carcinoma Expressing CEA

## Interventions

- **DRUG:** TF2 - 68 Ga-IMP-288:

## Key facts

- **NCT ID:** NCT01730612
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730612, "ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01730612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*